【摘要】 肝细胞癌(HCC)是最常见的原发性肝癌之一。经导管动脉化疗栓塞术(TACE)一直被用为中期HCC患者的一线治疗方法,而药物洗脱微球TACE(DEB-TACE)的临床应用近年来亦不断增加。本文对DEB-TACE的药物代谢动力学、微球选择、适应证和禁忌证及疗效评估进展进行综述。更多还原

【Abstract】 Hepatocellular carcinoma(HCC) is one of the most common primary liver carcinoma. Transcatheter arterial chemoembolization(TACE) has been used as the first-line treatment for patients with mid-term HCC. In recent years,clinical application of drug-eluting bead TACE(DEB-TACE) kept increasing. The pharmacokinetics, selection of microspheres, indications, contraindications and evaluation on therapeutic effect of DEB-TACE for treatment of HCC were reviewed in this article.更多还原